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Newborn screening for congenital adrenal hyperplasia (CAH) has high false-positive rates, 
necessitating confirmation of primary results. We developed a single LC-MS/MS assay for 
dried blood spots (DBS) that allows concurrent confirmation and differential diagnosis of 
CAH. All five steroids (cortisol, 21-deoxycortisol, 11-deoxycortisol, 4-androstenedione and 
17-hydroxyprogesterone) were baseline resolved and reliably determined (UHPLC: 
PerkinElmer Flexar FX-10; MS/MS: ABSCIEX QTRAP 5500; column: Phenomenex Kinetex 
XB-C18). In Hungary-Romania Cross-Border Cooperation Project (HU-RO 0802/008 
SCREENGEN), the 21-hydroxylase deficient form of CAH was confirmed in one of a total of 
163 samples tested positive in primary screening. Our validated assay can use the same DBS 
as in primary screening (2nd-tier test), eliminating the need for repeated blood sampling and 
accelerating diagnosis.  
 
Introduction 
Congenital adrenal hyperplasia (CAH), a severe inher ted disorder of cortisol biosynthesis, 
can cause death in early infancy (due to disturbed so ium homeostasis) and prenatal 
virilisation in affected girls and signs of a postnatal androgen excess in both sexes (caused by 
an accumulation of steroid precursors, metabolized to androgens) [1].  
Newborn screening for CAH is generally performed through measurement of the 
17-hydroxyprogesterone (17-OHP) level in dried blood spots (DBSs) by means of a 
fluorescence immunoassay (DELFIA®) [1]. However, the number of false-positives in 
primary CAH screening is high: CAH is confirmed in o ly around 1-2 of every 100 positive 
results [1]. Therefore, primary screening results for CAH based on a 17-OHP assay must be 
confirmed with a second method, preferably using the same DBS specimen as in the primary 
screening [1].  
Liquid chromatography–tandem mass spectrometry (LC-MS/MS) can effectively decrease the 
number of false-positives in CAH screening [1, 2, 3]. However, earlier assays could not 
differentiate between the two main forms of CAH, a 21-hydroxylase deficiency and an 
11β-hydroxylase deficiency, which together account for >99% of all cases [1]. This requires 
separation of 21-deoxycortisol (21-Deox) and 11-deoxyc rtisol (11-Deox), specific for these 
two forms of CAH [1]. Most previous assays for 21-Deox and 11-Deox did not allow analysis 
of DBSs [4, 5]; and those which did, achieved acceptable but not baseline resolution of these 
isobaric analytes [6].  
Accordingly, we aimed to develop a single LC-MS/MS assay for the concurrent confirmation 
and differential diagnosis of CAH through the analysis of 21-Deox, 11-Deox, cortisol (Cort), 
4-androstenedione (4-AD) and 17-OHP in DBS. We also set out to apply this method for 




newborn screening in the frame of the Hungary-Romania Cross-Border Cooperation Project 
(HU-RO) 0802/008 SCREENGEN. Cross-border cooperation may be expected to improve the 
effectiveness of newborn CAH screening and eliminate possible issues (high initial costs and 
the need for trained analysts) concerning the impleentation of the LC-MS/MS technique 
[7, 8, 9].  
 
Experimental 
For sample preparation, two spots 4.7 mm in diameter (corresponding to 13.6 µl blood) were 
punched out from filter cards and placed into 96-well round-bottom microtiter plates. For 
steroid extraction, 200 µl of the deuterated internal standard working soluti n was added to 
each vial. The plate was sealed and shaken for 50 min at ambient temperature. After 
centrifugation, the supernatant (150 µl) was transferred to a second plate and dried for 45 min. 
The underivatized residues were reconstituted in 45 µl methanol/water 20/80 (v/v), sealed and 
shaken for 20 min at room temperature.  
The analysis was performed on a PerkinElmer Flexar UHPLC system (two FX-10 binary 
pumps, solvent manager with a degasser, autosampler and thermostatic oven; all PerkinElmer 
Inc., Waltham, MA, USA), and an AB SCIEX QTRAP 5500 MS/MS triple quadrupole mass 
spectrometer, controlled by Analyst 1.6.1 software (both AB SCIEX, Framingham, MA, USA). 
Following optimization of the MS/MS settings, 15 µl of sample was analyzed using multi-step 
gradient elution (total assay time: 13 min) using a Phenomenex Kinetex XB-C18 
100x3.0 mm, 2.6 µm core-shell analytical column and a SecurityGuard Ultra Cartridge guard 
column (both Phenomenex, Torrance, CA, USA). Eluents A and B consisted of ultrapure 
water plus 0.1% formic acid, and methanol plus 0.1% formic acid, respectively.  
In the frame of the Hungary-Romania Cross-Border Cooperation Project, DBS samples from 
newborns screened in county Timis, Romania, and suspected of having CAH on the basis of 
the primary screening (17-OHP DELFIA® assay, Wallac Oy, PerkinElmer Inc., Turku, 
Finland), were sent to our laboratory. The reported LC-MS/ assay was applied as a 
second-tier test, using the same specimen as in the primary screening. After prompt 
determination of the steroid levels in Szeged, the results were immediately reported to the 
primary screening centre to facilitate early intervention. The Cross-Border Cooperation 
Project was approved by the Ethical Committees of all p rticipating institutions (the 
University of Szeged, the Louis Turcan Emergency Hospital for Children and the Vasile 
Goldis Western University of Arad).  
 
Results and discussion 
Traditionally, the confirmation of primary CAH screening results was based on LC-MS/MS 
findings of elevated levels of 4-AD and 17-OHP, a decreased level of Cort and an elevation in 
the ratio (4-AD+17-OHP)/Cort [3]. In contrast with 4-AD and 17-OHP, 21-Deox and 
11-Deox are specific markers for 21-OH and 11β-OH deficiencies, respectively [1]. Thus, 
their concurrent determination can improve the specificity of the assay and allow the 
differential diagnosis of the two most frequent forms of CAH [1].  
Previous assays for 21-Deox and 11-Deox have almost exclusively used serum samples [4] or 
urine [5]. However, serum and urine can be obtained only with a delay which can hamper 
early recognition and treatment. Instead, the analysis of the same DBS specimen as in the 
primary screening eliminates the need for repeated blood sampling, can shorten time to 
diagnosis and improve the cost- and time-effectiveness of screening [2]. The avoidance of 
repeated blood sampling in the large number of false-positive cases can eliminate unnecessary 
family anxiety and the accompanying increase in the frequency of hospitalization [9].  
We have successfully developed a single LC-MS/MS assay for the concurrent confirmation 
and differential diagnosis of CAH through the analysis of 21-Deox and 11-Deox in DBS 




(together with Cort, 4-AD and 17-OHP). This method was validated in terms of linearity, 
lower limit of detection (LLOD; 1.0-5.0 nM), lower limit of quantitation (LLOQ; 
2.5-12.5 nM), intra-assay precision (coefficient of variation, CV: <7%), inter-assay precision 
(CV: <10%), variation between injections (CV: <5%), retention time stability (CV: <1%) and 
extraction efficiency (CV: 69.7-85.2% for DBS calibrator vs methanolic standard; and 
75.3-90.4% for DBS calibrator vs. spiked whole blood). Excellent baseline resolution (Rs>1.5) 
was achieved for all five metabolites in DBSs: the Rs was 4.28 for the pair Cort and 21-Deox; 
3.46 for the pair 21-Deox and 11-Deox; 5.68 for the pair 11-Deox and 4-AD; and 6.51 for the 
pair 4-AD and 17-OHP. A representative LC-MS/MS chromatogram of a DBS calibrator is 
presented in Figure 1.  
 
 
Figure 1. Representative LC-MS/MS chromatogram of a DBS calibr tor.  
Peak numbers: 1: Cort; 2: 21-Deox; 3: 11-Deox; 4: 4-AD; 5: 17-OHP (black peaks: unlabelled 
analytes; unfilled peaks: deuterated internal standards). 
 
In addition, our LC-MS/MS assay proved applicable for the confirmation and differential 
diagnosis of CAH in cross-border cooperation for newborn screening. A total of 163 newborn 
DBS samples (including 16 prematures) submitted for second-tier testing were tested with the 
present assay. The results were compared with referenc  values of healthy mature newborns 
and prematures (related to gestational age). The classi  21-hydroxylase deficient form of 
CAH could be confirmed in one sample on the basis of the markedly elevated levels of 
21-Deox, 4-AD and 17-OHP, the increased ratio (21-Deox+17-OHP)/Cort and the decreased 
Cort level (11-Deox concentration and ratio 11-Deox/Cort were normal). All other samples 
proved to be false-positives; an 11β-hydroxylase deficiency was not detected.  
 
Conclusion 
An LC-MS/MS method with excellent resolution of 21-Deox and 11-Deox in DBS has been 
developed, allowing the simultaneous confirmation of CAH and reliable differentiation 
between its two main forms, the 21-hydroxylase and 11β-hydroxylase deficiencies. The assay 
can use the same DBS as in the primary screening (second-tier approach), which can facilitate 




early therapeutic intervention, improve the cost- and time-effectiveness of screening, and 
eliminate unnecessary family anxiety by decreasing the high recall rates caused by 
false-positives. Our method was successfully applied to clinical DBS samples in cross-border 
cooperation for newborn screening for CAH. The specificity and sensitivity of LC-MS/MS 
and the use of analyte ratios are expected to facilitate the diagnosis of mild, non-classic CAH.  
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